Clarametyx Biosciences is a biopharmaceutical company focused on developing novel immune‑enabling therapies targeting bacterial biofilms that drive chronic respiratory diseases such as cystic fibrosis. The company advances its pipeline through pre‑clinical and early‑stage clinical programs, aiming to modify disease progression rather than merely alleviate symptoms. Recent announcements include positive topline data from a Phase 2a study of CMTX‑101 and significant Series A financing to accelerate development.
Clarametyx Biosciences is profiled on the APIs.io network. Tagged areas include Respiratory Diseases, Clinical Trials, Drug Development, and Biofilms.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: clarametyx-biosciences
name: Clarametyx Biosciences
description: Clarametyx Biosciences is a biopharmaceutical company focused on developing novel immune‑enabling therapies targeting
bacterial biofilms that drive chronic respiratory diseases such as cystic fibrosis. The company advances its pipeline through
pre‑clinical and early‑stage clinical programs, aiming to modify disease progression rather than merely alleviate symptoms.
Recent announcements include positive topline data from a Phase 2a study of CMTX‑101 and significant Series A financing
to accelerate development.
url: https://raw.githubusercontent.com/api-evangelist/clarametyx-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment pass 2026-10-08 (modular-v1; was harvest)
specificationVersion: '0.20'
created: '2026-10-08'
modified: '2026-10-08'
tags:
- Respiratory Diseases
- Clinical Trials
- Drug Development
- Biofilms
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Hosts
url: hosts/clarametyx-biosciences-hosts.yml
- type: DomainSecurity
url: security/clarametyx-biosciences-domain-security.yml
- type: Website
url: https://clarametyx.com
- type: PrivacyPolicy
url: https://clarametyx.com/privacy-policy/
apis: []
x-coverage:
state: none
reason: no-developer-program
method: derived
generated: '2026-10-08'
generator: derive-coverage.py (pre-flight evidence)
detail: the company publishes no developer documentation host and no machine-readable contract on its own domain
evidence:
- url: https://clarametyx.com
status: 200
- url: https://forgeglobal.com/clarametyx-biosciences_stock/
status: 200
x-enrichment:
date: '2026-10-08'
status: enriched
artifacts_added: 6
pass: modular-v1
engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →